Northern Trust
CADL icon

Northern Trust’s Candel Therapeutics CADL Stock Holding History

Northern Trust’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.58M Buy
323,154
+27,716
+9% +$151K ﹤0.01% 3099
2025
Q4 		$1.67M Sell
295,438
-11,337
-4% -$61K ﹤0.01% 3104
2025
Q3 		$1.56M Buy
306,775
+18,912
+7% +$109K ﹤0.01% 3169
2025
Q2 		$1.46M Buy
287,863
+52,327
+22% +$269K ﹤0.01% 3181
2025
Q1 		$1.33M Buy
235,536
+70,515
+43% +$576K ﹤0.01% 3142
2024
Q4 		$1.43M Buy
165,021
+6,250
+4% +$36.9K ﹤0.01% 3208
2024
Q3 		$1.1M Buy
158,771
+115,326
+265% +$716K ﹤0.01% 3323
2024
Q2 		$269K Buy
43,445
+23,938
+123% +$180K ﹤0.01% 3750
2024
Q1 		$30.8K Sell
19,507
-110
-0.6% -$163 ﹤0.01% 4294
2023
Q4 		$28.8K Hold
19,617
– – ﹤0.01% 4328
2023
Q3 		$18K Hold
19,617
– – ﹤0.01% 4345
2023
Q2 		$24.7K Hold
19,617
– – ﹤0.01% 4369
2023
Q1 		$26.5K Buy
19,617
+5,134
+35% +$10K ﹤0.01% 4400
2022
Q4 		$25.9K Hold
14,483
– – ﹤0.01% 4433
2022
Q3 		$45K Hold
14,483
– – ﹤0.01% 4345
2022
Q2 		$47K Buy
14,483
+1,028
+8% +$4.12K ﹤0.01% 4426
2022
Q1 		$68K Hold
13,455
– – ﹤0.01% 4454
2021
Q4 		$105K Buy
+13,455
New +$131K ﹤0.01% 4401

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust's CADL Position: Q1 2026 in Review

Northern Trust increased its Candel Therapeutics (CADL) stake by 9.4% in Q1 2026, buying an estimated $151K and bringing the position to 323,154 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #3099.

Northern Trust first reported a position in CADL in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.67M in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Northern Trust held 323,154 shares of Candel Therapeutics worth $1.58M as of Q1 2026.
  • Northern Trust bought 27,716 Candel Therapeutics shares in Q1 2026, an estimated $151K.
  • Candel Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3099 holding.
  • Northern Trust first reported a position in Candel Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Northern Trust's Candel Therapeutics position peaked at $1.67M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.